close

Enter

Log in using OpenID

Small Molecule Cancer Drugs Market Size & Share to See Modest Growth Through 2027

embed
Cancer is a chronic condition that involves abnormal growth of cell. Interference due to genetic changes causes uncontrollable growth of cells and results into formation of a mass called tumor. The tumor is malignant type, it is capable to spread al
Small Molecule Cancer Drugs Market To Register
Unwavering Growth During in Global by 2027
Small Molecule Cancer Drugs Market, by Drug Class (Alkylating Agents, Plant
Alkaloids, Antitumor Antibiotics, Antimetabolites, Topoisomerase Inhibitors, and
Others), by Route of Administration (Oral and Injectable), by Distribution
Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and
by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and
Africa) – Size, Share, Outlook, and Opportunity Analysis, 2019 – 2027
Cancer is a chronic condition that involves abnormal growth of cell. Interference due to genetic
changes causes uncontrollable growth of cells and results into formation of a mass called tumor. The
tumor is malignant type, it is capable to spread all over the body. Most of the cancer occur due to
genetic mutation, induced due to environmental factors or lifestyle, or it can be hereditary also. It is
classified into four categories on the basis of its origin – 1) Carcinoma (begins in skin or tissue) 2)
Sarcoma (begins in connective tissues) 3) Lymphoma (begins in lymphatic system) 4) Leukemia
(begins in blood).
Global Small Molecule Cancer Drugs Market Drivers
Approvals for small molecule cancer drugs by regulatory bodies to key players are expected to boost
the global small molecule cancer drugs market growth. For instance, in May 2019, U.S. Food & Drug
Administration (FDA) approved a drug, Piqray in combination with fluvestrant, which is manufactured
by Novartis AG. It is the first ever drug that is specifically being used for the treatment of HR/HER2-,
PIK3CA mutated advanced breast cancer.
Similarly, in April 2019, Janssen Pharmaceutical Company received U.S. FDA approval for Balversa
(erdafitinib). It is indicated for the treatment of FGFR3 or FGFR2 mutated, locally advanced urothelial
carcinoma. The type of study was multicenter, open-label, single-arm trial and comprised 87
participants diagnosed with locally advanced or metastatic urothelial carcinoma and had progressed on
or after at least one prior chemotherapy.
Request For a Sample Copy of This Business Report @
https://www.coherentmarketinsights.com/insight/request-sample/2754
Global Small Molecule Cancer Drugs Market Key Players
Some of the major players operating in the small molecule cancer drugs market include, Otsuka
Pharmaceutical Co. Ltd, Eli Lilly and Co, Janssen Research and Development LLC, Novartis AG,
Pfizer Inc., SANOFI AVENTIS US LLC, Baxter Healthcare Corp., Emcure Pharmaceuticals Ltd.,
AstraZeneca, Kyowa Kirin Inc., and HQ Specialty Pharma Corp
Global Small Molecule Cancer Drugs Market Taxonomy
The global small molecule cancer drugs market is segmented on the basis of drug class, route of
administration, distribution channel, and regions.
By Drug Class
•Alkylating Agents
•Plant Alkaloids
•Antitumor Antibiotics
•Antimetabolites
•Topoisomerase Inhibitors
•Others
By Route of Administration
•Oral
•Injectable
By Distribution Channel
•Hospital pharmacies
•Retail pharmacies
•Online pharmacies
Global Small Molecule Cancer Drugs Market Regional Analysis
North America is expected to hold a dominant position in global small molecule cancer drugs market,
owing to initiatives taken by other organizations related to cancer drugs. For instance, in June 2019,
American Cancer Society partnered with Ovarian Cancer Research Alliance to fund research activities
related to detection, treatment and prevention of ovarian cancer. Its goal is to raise funds for research
activities, so as to support them for investigation of drugs for ovarian cancer. Hence, such initiatives
may have a positive influence on the global small molecule cancer drugs market growth.
Global Small Molecule Cancer Drugs Market Restraints
Side-effects of drugs is expected to hamper the global small molecule cancer drugs market growth. The
side-effects depend mainly upon the type of cancer and the overall health of the patient. It can cause
muscle pain, headache, fatigue, mouth sores, nausea, vomiting, throat sores, diarrhea, and constipation.
As these drugs effect healthy cells, in turn, affecting the process of regenerating new blood cells.
Hence, this factor may obstruct the global Small Molecule Cancer Drugs Market growth.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]
Author
ravikiran
ravikiran298   documents Email
Document
Category
Health and Medicine
Views
2
File Size
378 KB
Tags
molecule
1/--pages
Report inappropriate content